Ignite Creation Date:
2024-05-06 @ 8:26 PM
Last Modification Date:
2024-10-26 @ 3:27 PM
Study NCT ID:
NCT06381141
Status:
RECRUITING
Last Update Posted:
2024-04-24
First Post:
2024-04-02
Brief Title:
A Study of CLN-619 Anti-MICAMICB Antibody in Patients With Relapsed and Refractory Multiple Myeloma
Sponsor:
Cullinan Therapeutics Inc
Organization:
Cullinan Therapeutics Inc
Study Overview
Official Title:
A Phase 1b Multicenter Open-Label Study to Investigate the Safety and Efficacy of CLN-619 Anti-MICAMICB Antibody in Patients With Relapsed and Refractory Multiple Myeloma
Status:
RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A Phase 1b Multicenter Open-Label Study to Investigate the Safety and Efficacy of CLN-619 anti-MICAMICB Antibody in Patients with Relapsed and Refractory Multiple Myeloma
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None